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Background: Rheumatoid arthritis (RA) is a chronic systemic auto- immune disease characterized by joint synovitis.
Recent evidence suggests that rheumatoid arthritis synovial fibroblasts (RASFs) promote joint destruction. In this
study, we investigated the role of microRNA-26b (miR-26b) in cell proliferation and inflammatory cytokine secretion
using patient-derived Rheumatoid arthritis fibroblast-like synoviocyte (RAFLS) to understand pathways influencing
rheumatoid arthritis.
Methods: RAFLS were cultured in vitro and transfected with miR-26b mimics (experimental group) and negative
sequence (control group). The protein levels of Wnt4, Wnt5ɑ, GSK-3β, CyclinD1, Ser9-GSK-3β and β-catenin were
detected by western blot analysis. Tumor Necrosis Factor-ɑ (TNF-ɑ), IL- 1β, and IL-6 levels were quantified by Enzyme-
linked Immunosorbent Assay (ELISA). RAFLS proliferation and apoptosis were measured by 3-[4, 5-dimethylthiazol-2-yl]-2,
5-diphenyl tetrazolium bromide (MTT) assay and flow cytometry, respectively.
Results: GSK-3β and CyclinD1 expression levels were lower in miR-26b mimic group compared to Mock group and
negative control (NC) group. Conversely, GSK-3β and CyclinD1 expression levels were markedly higher in the miR-26b
inhibitor group compared to Mock and NC group (P < 0.05). Transfection of miR-26b mimics significantly increased the,
levels of Ser9-GSK-3β and β-catenin in comparison to Mock and NC groups, while transfection of miR-26b inhibitors
showed the opposite effect. In miR-26b mimic group, TNF-α, IL- 1β and IL-6 levels were lower than the Mock and NC
groups, while in miR-26b inhibitor group, these cytokine levels were higher than the Mock and NC groups (P < 0.05).
Transfection of miR-26b mimics significantly reduced the cell proliferation of RAFLS, compared to the Mock and NC
groups, and miR-26b inhibitors increased the proliferative capacity of RAFLS compared to Mock and NC groups (P < 0.05).
The miR-26b mimic group exhibited higher RAFLS apoptosis rate compared to Mock and NC group and miR-26b inhibitor
group showed significantly lower RAFLS apoptosis rate compared to Mock and NC groups (P < 0.05).
Conclusions: MiR-26b regulates β-catenin and CyclinD1 levels by inhibiting GSK-3β expression, which in-turn alters the
Wnt/GSK-3β/β-catenin pathway to lower RAFLS proliferation and elevate cell apoptosis and the secretion of TNF-α,IL-1β
and IL-6 cytokines. Therefore, our results show that miR-26B plays a central role in inhibiting the inflammation associated
with rheumatoid arthritis.
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9063056861547150
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Rheumatoid arthritis (RA) is a chronic systemic auto-
immune disease characterized by joint synovitis [1, 2]. The
clinical manifestations of RA includes joint swelling and
pain caused by synovitis, cartilage destruction, joint space
narrowing, joint stiffness, deformity and dysfunction, which
are directly related to primary chronic low-grade inflamma-
tion [3, 4]. RA affects 0.5-1 % of adults in developed coun-
tries and approximately 5–50 per 100,000 population in
developing countries each year [5]. RA onset is rare under
the age of 15, but its incidence shows a steady increase
with age until 80, with women 3–5 times more susceptible
than men [6]. The exact cause of RA is still unknown, but
genetic factors, such as human leukocyte antigen-DR4
(HLA-DR4) and other non-HLA genes including protein
tyrosine phosphatase, non-receptor type 22 (PTPN22) and
peptidyl arginine deiminase, type IV (PADI4), are sus-
pected as major contributing factors [7, 8]. Non-genetic
factors also contribute significantly to RA and include
Epstein-Barr virus (EBV) and Human Herpes Virus 6
(HHV-6) infections, hormonal infleunces, smoking, cold
temperatures and trauma [9, 10]. Previous studies show
that loss of balance in proliferation and apoptosis of syn-
ovial fibroblast (SF) and abnormal secretion of various
cytokines play key roles in RA pathogenesis. Multiple sig-
naling pathways are activated during RA development [11,
12]. Synovial tissue from RA patients shows infiltration by
macrophages, T cells, and B cells, proliferation of cells
lining the synovium, and production of inflammatory
cytokines such as tumor necrosis factor α (TNFα) and
interleukin-1β (IL-1β) [13, 14]. Interestingly, inhibition of
these cytokines ameliorates the clinical symptoms RA,
strongly supporting the central role of cytokines in RA
[15]. Rheumatoid arthritis synovial fibroblast (RASFs) ac-
tivity promotes joint destruction and increased expression
of proinflammatory pathways and secretion of matrix-
destructive enzymes is a common feature associated with
the disease [16]. Recent evidence suggests that miRNA
dysregulation may contribute to RA etiopathogenesis and
therefore, a better understanding of pathways regulated by
miRNAs might shed light on RA pathogenesis and help
identify effective RA treatments [17].
MicroRNAs (miRNAs) are small, non-coding endogen-
ous RNAs of 20 ~ 24 nucleotides in length and regulate
gene expressions at the post-transcriptional level [18].
MiRNAs bind to 3′ untranslated regions (3′ UTRs) of
their target mRNAs and either block translation and/or
promote target mRNA degradation [19]. MiRNAs play
important roles both in pathological and normal physio-
logical processes such as embryonic development, energy
homeostasis, metabolism of sugar and lipid as well as
tumorigenesis [20–23]. Several miRNAs modify cell be-
havior by regulating the nuclear factor-kB (NF-κB) path-
way [18]. For instance, miR-30e, miR-182, and miR-301apromote NF-κB activity to enhance tumor growth, inva-
siveness or angiogenesis [24–26]. Joanna Stancz et al.
observed dysregulated expression of miRNA miR-155 and
miR-146a in synovial tissue, synovial fibroblasts and
monocytes of rheumatoid joints [16]. Previous studies
showed that the miR-26 family, consisting of miR-26a and
miR-26b, is down-regulated in several cancers such as he-
patocellular carcinoma (HCC), melanoma, nasopharyngeal
carcinoma and breast cancer [27–31]. Although the cellu-
lar functions of miR-26b remain elusive, miR-26b inhibits
NF-κB pathway in HCC cells by suppressing TAK1 and
TAB3 expression, and down-regulation of miR-26b sup-
pressed apoptosis in HCC cells [18]. Thus far, the main
role of miR-26b was described in cancers. However, due
to the close relationship between cancer and inflammatory
pathway, we investigated whether miR-26b influenced
cell proliferation and inflammatory cytokine secretion




The study was approved by the Institutional Review Boards
(IRBs) of Linyi People’s Hospital. Written informed con-
sent was obtained from each eligible participant and the
study was performed in accordance with the Declaration
of Helsinki.
Culture of rheumatoid arthritis fibroblast-like synoviocytes
(RAFLS)
Human synovial tissues from the affected joints were
collected from patients admitted at the Linyi People’s
Hospital signed informed consent forms were obtained
before the procedure. The diagnosis of RA in these patients
was according to American Rheumatism Association 1987
revised criteria for classification of rheumatoid arthritis
[32]. Synovial tissues were obtained from RA patients at
surgery. They collected tissue samples were minced and
digested with 2.5 g/L trypsase for 2 h at 37 °C and cells
were collected after centrifugation and cultured in Dulbec-
co’s minimum essential medium (DMEM) in 5 % CO2 at
37 °C. The cells were cryopreserved between 3rd – 8th
passage and cells within these passages were chosen for
all experiments.
Cell grouping and transfection
The experimental set-up consisted of 4 groups: the Mock
group, negative control (NC group transfected with miR-
26b negative control sequence), miR-26b mimics group
(transfected with miR-26b mimics) and the miR-26b in-
hibitor group (transfected with miR-26b inhibitor). RAFLS
in logarithmic phase cultured in DMEM with 10 % FBS
were detached to for single cell suspension. They were
adjusted to 1 × 106 cell/ml concentration and seeded
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formed when the seeded cells reached 80 % confluency.
Lipofectamine 2000 (Invitrogen Company, USA) was
used to transfect the cells. Plasmids (1 μg) carrying the
respective miR-26b sequences were mixed separately
with serum-free medium and 2.5 μl lipofectamine 2000
and incubated at room temperature for 15 min under
serum-free conditions to form transfection complexes.
The RAFLS were washed twice with PBS and the corre-
sponding transfection complexes were added to each
well. Complete DMEM media was replaced 6 h later.
The transfection efficiency was verified by fluroscence
microscopy at 24 h and 48 h, and cells at 48 h post-
transfection were used for further analsis.
Real-time quantitative polymerase chain reaction (PCR)
technique for measurement of miR-26b expression
Trizol reagent was used to purify total RNA and 0.05 μg
of the total RNA was used for first strand cDNA synthe-
sis using SuperscriptII reverse transcriptase. Specific
primers for miRNA for real-time quantitative PCR and
first strand cDNA synthesis were based on published
sequences. Light Cycler PCR and the reagents were
lightcycler-faststart DNA master SYBR green were from
Roche. Reaction conditions were: magnesium concentration
was 3 mmol/L, primer concentrations were 0.25 μmol/L;
denaturation for15 s at 95 °C, 60 °C and then anneal for
30 s, repeated 40 cycles. Solubility curve were pro-
tracted at 70 °C to 95 °C and PCR products were verified
by electrophoresis.
Dual-luciferase enzyme assay system for reporter gene
analysis
The cells were transfected as mentioned above and the
transfected cells at 48 h were washed with 1 × PBS. The
cells were treated with lysis buffer and Dual-Luciferase®
Reporter Assay (Promega) was performed, using lumin-
ometer, to measure the activity of luciferase. The firefly
luciferase activity values were recorded and compared to
the Ranilla luciferase activity to quantify transfection
efficiency.
Western blot
Wnt4, Wnt5α, GSK-3β, CyclinD1, Ser9-GSK-3β and β-
catenin protein levels were detected by western blot ana-
lysis. RIPA lysis buffer was used to exact proteins and
BCA method was used to estimate total protein concen-
tration. The samples were electrophoresed in 10 %
SDS-PAGE gels (100v, 100 min). The proteins were
transferred to PVDF membranes (Invitrogen company)
and blocked with 10 % skimmed milk. Next, corresponding
primary antibodies (1: 1000) were used to detected the
protein, the membranes were washed with TBST thrice
and incubated with horseradish peroxidase (HRP)-labeledsecondary antibody for 1 h and DAB staining was per-
formed after washing the membranes, followed by record-
ing the results using gel imaging system. The quantitative
measurement of the proteins was as follows: relative ex-
pression of the target protein = grey level of target band/
grey level of the same sample reference.Experimental Study of Enzyme-linked Immunosorbent
Assay (ELISA) method
Tumor Necrosis Factor-α (TNF-α), IL- 1β, and IL-6
levels were detected using ELISA kit (BD Company,
USA). The cells were centrifuged at 1500 rpm for 5 min
in 4 °C. The samples were resuspended at 1 × 106 cells/
ml and seeded into 12-well plates. Criss-cross serial dilu-
tion analysis was adopted to ensure the cell numbers
and concentration of labelled complex. From each well,
100 μl cell suspensions were added to ELISA plate, cen-
trifuged at 1500 rpm for 1 min, incubated to allow coat-
ing and then the supernatants were removed. To each
well, 100 μl of antibody solution diluted in PBS was used
and incubated for 90 min at 4 °C. Next, 100 μl enzyme-
antibody complex diluted in PBS was added to each well
and incubated for 90 min at 4 °C and washed 3 times. A
100 μl volume of substrate solution was added to each
well and incubated for 1 h at room temperature and the
detection was at 450 nm to measure the absorbance.Cell proliferation detected by 3-[4, 5-dimethylthiazol-2-yl]-2,
5-diphenyl tetrazolium bromide (MTT) assay
RAFLS in each group were collected and the cell con-
centration was adjusted to 1 × 106 cells/ml, and inocu-
lated into 96-well culture plate (100 μL/well) for various
times. The cells were incubated with 20 μL MTT (5 mg/ml,
Sigma Chemicals Co.) for 4 h. Next, 200 μl DMSO
were added to each well and incubated at room
temperature for 10 min in dark to dissolve the com-
plexes. To plot the MTT curves, absorbance values
were used as ordinate and time interval was the ab-
scissa. All samples were in triplicates and the experi-
ment was repeated 3 times.Cell apoptosis assayed by flow cytometry
AnnexinV-FITC (Sigma Chemicals Co) was used accord-
ing to manufacturer’s instructions. Briefly, cells from
each group were washed 3 times in pre-cooled PBS. A
volume of 1 μl 1 × annexin V was combined with buffer
solution, centrifuged to discard the liquid supernatant
and 200 μL binding buffer added to resuspend the cells.
A volume of 10 μL annexin V-FITC and 5 μl PI (5 mg/L)
were added, mixed and incubated for 30 min in dark,
followed by flow cytometry (Olympus company) to quan-
tify the apoptosis rate.
Fig. 2 The expression of miR-26b in each transfection group, *, the
comparison between Mock group and NC group, P < 0.05 (NC,
negative control)
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All statistical analyses were performed using SPSS 18.0
software (SPSS, Inc., Chicago, IL, USA). All data were
expressed as mean ± SEM. Differences between groups
were measured using independent samples t-test. A
P < 0.05 value denoted statistically significant difference.
Results
Expression of green fluorescent protein (GFP) after RAFLS
transfection in each group
Following the transfection of RAFLS with various plas-
mids as indicated, the GFP marker expressed by the re-
combinant plasmid was used to determine transfection
efficiency by fluorescence microscopy (Fig. 1). After 24 h
of transfection, GFP express was visible and this expres-
sion significantly increased after 48 h.
Confirmation of miR-26b expression by real-time
quantitative PCR
Figure 2 shows that the expression level of miR-26b in
both Mock group and NC group were 1.05 ± 0.05 and
1.04 ± 0.06, respectively (P > 0.05). The expression level
in mimic group was 2.56 ± 0.15, which was higher than
the Mock group and NC group (all P < 0.05). In miR-26b
inhibitor group, miR-26b expression level was 0.23 ±
0.04, significantly lower than Mock and NC groups (all
P < 0.05).
Confirmation of target-gene of miR-26b by dual-luciferase
reporter gene system
Using bioinformatics Target Scan software (http://
www.targetscan.org), the potential target-genes of miR-
26b were analyzed. The 3′-UTR of GSK-3β was highly
conserved between different species and contained the
binding site for mir-26b (Fig. 3a). As shown in Fig. 3b,
recombinant plasmids containing Wt- miR-26b/GSK-3β
and Mut- miR-26b/GSK-3β were constructed and
cotransfected with miR-26b mimics. The results of the
dual luciferase activity assays indicated that miR-26b
mimics did not influence luciferase activity in Mut- miR-24h
48h
NC miR-26b mimic miR-26b inhibitor
Fig. 1 Expression of green fluorescent protein (GFP) in RAFLS at 24
and 48 h post-transfection26b/GSK-3β, but sharply decrease luciferase activity when
the 3′-UTR contained Wt- miR-26b/GSK-3β (all P < 0.05).Expression of nt4, Wnt5ɑ, GSK-3β, CyclinD1,
phosphorylationSer9-GSK-3βand β-catenin
As shown in Fig. 4, Wnt4 and Wnt5 expression level in
each group showed no significant differences (P > 0.05).
By contrast, GSK-3β and CyclinD1 expression levels in
miR-26b mimic group were lower than the Mock group
and NC group (all P < 0.05). Conversely, the expression
level of GSK-3β and CyclinD1 in the miR-26b inhibitor
group was higher than the Mock and NC group (P < 0.05).
In the miR-26b mimic group, expression levels of Ser9-
GSK-3β and β-catenin were higher than Mock and NC
groups (all P < 0.05), while in the miR-26b inhibitor group,
their levels were significantly lower (all P < 0.05). The
expression of GSK-3β, CyclinD1, Ser9-GSK-3β and β-
catenin were not different statistically (all P > 0.05).TNF-ɑ, IL- 1β and IL-6 levels
TNF-α, IL- 1β and IL-6 levels were quantified by ELISA
(Fig. 5). TNF-α, IL- 1β and IL-6 levels showed no statis-
tical differences between the Mock and NC groups (all
P > 0.05). However, in the miR-26b mimic group, these
cytokine levels were significantly lower than the Mock
and NC groups (all P < 0.05). On the other hand, in the
miR-26b inhibitor group, the cytokines levels were
higher than in the Mock and NC groups (all P < 0.05).Proliferation capacity of RAFLS
The RAFLS cell proliferation was measured by MTT
method, as shown in Fig. 6. We observed no differences
in cell proliferation capacity between the Mock group
and NC group (P > 0.05). In miR-26b mimic group, the
RAFLS cell proliferation capacity was significantly lower
than the Mock and NC groups (all P < 0.05). In the miR-
26b inhibitor group, the proliferation capacity of RAFLS
was significant higher than Mock and NC groups (all
P < 0.05).
Fig. 3 GSK-3β is the target of miR-26b. a: the comparison between miR-26b and 3′UTR of GSK-3β, the red part is complementary sites (core sequence, also
can be regarded as miR-26b is act on the hypothetical gene loci of GSK-3β gene; GSK-3β 3′-UTR is highly conserved between species) b: Dual-luciferase
assay for reporter gene analysis; detected in RAFLS cotransfected miR-26b mimics and GSK-3β 3′-UTR Wt/Mu plasmid; miR-26b inhibited activity
of luciferase containing Wt 3′-UTR, *P < 0.05, while Mut plasmid activity of luciferase showed no change. NC, negative control
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As shown in Fig. 7, RAFLS apoptosis rates between the
Mock and NC groups were not significantly different
(P > 0.05). However, in the miR-26b mimic group, RAFLS
apoptosis was markedly higher than observed in the Mock
and NC groups (all P < 0.05). In the miR-26b inhibitorFig. 4 Expression of Wnt4, Wnt5ɑ, Ser9-GSK-3β, CyclinD1 and β-catenin, *, th
blot of Wnt4, Wnt5ɑ, Ser9-GSK-3β, CyclinD1 and β-catenin expression; b, r
c, relative expression of Ser9-GSK-3β andβ-catenin in the 4 groups; d: rela
Mock, NC, miR-26b mimic and miR-26b inhibitor group). NC, negative congroup, RAFLS apoptosis was significant lower than the
Mock and NC groups (all P < 0.05).
Results and discussion
RA is a chronic systemic disease characterized by in-
flammatory synovitis [33]. RA pathology is influenced bye comparison between Mock group and NC group, P < 0.05. a, Western
elative expression of Wnt4 and Wnt5ɑ in the 4 experimental groups;
tive expression of GSK-3β and CyclinD1in the 4 groups (4 groups:
trol
Fig. 5 The ELISA results of TNF-ɑ,L- 1βand IL-6 levels, *, the comparison
between Mock group and NC group, P< 0.05. NC, negative control
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cellular pathways, viral infections, genetic factors, hormonal
influences and psychological state [34]. RA is associated
with significant comorbidities, articular damage, disability
and increased mortality [35]. MiRNAs are a new class of
small no-coding single-stranded RNAs 13–21 nucleotides
in length and function as post-transcriptional regulators
of gene expression by complementary binding to target
mRNAs [36, 37]. MiRNAs are excellent candidates as mo-
lecular biomarkers for diagnosis and prognosis in several
human pathological conditions [38, 39]. Shang et al.
showed that miRNAs also influence the disease course in
severe joint diseases, including osteoarthritis and RA,
through regulating diverse cellular processes such as cell
proliferation, differentiation, signal transduction, immune
response and apoptosis [40].
In our study, miR-26b elevated the expression of β-
catenin and CyclinD1 by lowering GSK-3β expression,
which in-turn activated Wnt/GSK-3β/β-catenin pathway,
inhibited RAFLS apoptosis and led to increased secretion
of TNF-α,IL-1β and IL-6. Thus, miR-26b plays a central
role in pathways controlling inflammation in reumatoid
arthritis. Wnt is a secreted protein important in cell prolif-
eration, differentiation, cell morphology, cell adhesion, cell
motility and development [41]. In addition, β–catenin has
a dual function in regulating gene transcription and in
cell–cell adhesion [42]. As a component of the cadherin
protein complex, β–catenin is an intracellular signalFig. 6 The MTT assay results for cell proliferation, *, comparison
between Mock group and NC group, P < 0.05. NC, negative controltransducer of cell polarity and also functions in the Wnt
signaling pathway [43]. Jong Hui Suh et al. demonstrated
that miR-26a, which has the same core sequence with
miR-26b, is indeed a functional gene product and is
capable of binding to GSK-3 β and directly regulating its
expression [44]. GSK-3β is a regulator of β-catenin levels
and Wnt-induced intracellular signaling sequesters β-
catenin from GSK-3β and promotes its nuclear accumula-
tion, allowing β-catenin to complex with T-cell factor/
lymphocyte enhancer binding factor (TCF/LEF) to activate
transcription of target genes [45]. GSK-3β, functions at
the upstream step of Wnt/β-catenin signaling pathway
and is one of the most important negative regulatory com-
ponent in the cell to control β-catenin function [46]. GSK-
3β directly regulates β-catenin availability in the nucleus,
depending on the intensity of the Wnt signaling pathway,
by phosphorylating β-catenin in the cytosol and targeting
it for ubiquitin-dependent proteolysis [47, 48]. GSK-3β
was later found to regulate key signaling events relating to
multiple aspects of cellular function, including protein
synthesis, cytoskeletal integrity and gene expression [49].
In this study, transfection of miR-26b led to a significant
increase in total GSK-3β and a decrease in the inhibitory
phosphorylation on Ser9-GSK-3β, strongly influencing
Wnt/GSK-3β/β-catenin pathway. Therefore, we believe
that miR-26b is specific to this pathway and has a promin-
ent role in inhibiting RA synovial inflammation. Consist-
ent with this interpretation, Wnt-4 and Wnt-5α showed
no significant differences in our study. Wnt-5α alters cell
morphology by reducing cell adhesion and members of
this family activate the non-canonical Wnt pathway.
Our study revealed that transfection of miR-26b signifi-
cantly inhibited NF-κB activity, as judged by the sharply
decreased levels of tumor necrosis factor (TNF)-α, IL-1β
and IL-6. Although the exact mechanism of this effect
need to be further investigated, we believe that miR-26b is
intimately involved in RA progression and miR-26b based
strategies have the potential to be highly effective against
synovium inflammation in RA, consistent with earlier ob-
servations by Turner-Brannen et al. [50]. Our study is
also supported by Tomoyuki Nakasa et al., who presented
convincing results that NF-κB activity is critical for the
initiation and maintenance of chronic inflammation in RA
synovial tissue [15].
It is interesting to note a significant decrease in RASF
proliferation after miR-26b transfection. Compared with
healthy individuals, hyperplasia of synovial cells is in-
duced by excessive cell proliferation or/and defects in
apoptosis, leading to synovial lining thickness of up to
10–15 cell layers [51, 52]. Synovial hyperplasia can also
promote the synovium attachment to the adjoining car-
tilage and bone, which causes joint dysfunction [53].
Clinically, arthroscopic synovectomy is very affective in
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Fig. 7 Effects of miR-26b on RAFLS apoptosis (Q1:necrotic cells; Q2:apoptotic cells; Q3:living cells; Q4:early apoptotic cells. Apoptosis rate of RAFLS
in miR-26b inhibitor group is lower than Mock and NC group, while the rate in miR-26b mimic group is higher than Mock and NC group;
apoptosis rates between Mock and NC group showed no significant differences). NC, negative control
Sun et al. Diagnostic Pathology  (2015) 10:72 Page 7 of 9suggesting that hyperplasia of synovial cells plays an im-
portant role in RA pathology and joint function [54].Conclusions
Based on our results, we propose that the proliferation
of synovial fibroblast is a significant event in RA and in-
hibition of hyperplasia may be an effective treatment for
RA. MiR-26b may be useful to down-regulate SF hyper-
plasia and inhibit synovium inflammation. In summary,
miR-26b inhibits RASF proliferation and reduces secre-
tion of inflammatory cytokines, including TNF-α,IL-1β
and IL-6, via inhibiting Wnt/GSK-3β/β-catenin pathway
through regulating GSK-3β level.Competing interests
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